Recombinant DNA technology has revolutionized the production and use of a number of therapeutic proteins, including cytokines and cellular growth factors. These proteins have similar or identical biologic activities as their natural counterparts and are particularly useful for treating patients who
No takes yet. Share an insight, caveat, or question.
Thorpe et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: